Endologix
Endologix is a US-headquartered, Deerfield-owned medical device company developing minimally invasive endovascular stent grafts and percutaneous bypass systems for abdominal aortic aneurysm repair and peripheral arterial disease, sold directly to hospitals and vascular specialists.
- Company typePrivate
- Founded1992
- HeadquartersIrvine, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endologix does
Endologix is a US-headquartered, privately held medical device company (wholly owned by Deerfield Management since October 2020) that develops and manufactures minimally invasive treatments for vascular disease, with a primary focus on abdominal aortic aneurysm (AAA) repair and peripheral arterial disease (PAD). The company's commercial portfolio centers on three platforms: the AFX2 Endovascular AAA System (bifurcated unibody design with ActiveSeal technology), the ALTO Abdominal Stent Graft System (Adaptive Sealing Technology, 13F delivery profile, and a 7mm neck-length indication for complex anatomies), and the DETOUR System (acquired via PQ Bypass in 2021, providing the first fully percutaneous transmural arterial bypass for long femoropopliteal lesions). In May 2026, Endologix acquired the Pounce Thrombectomy System from Surmodics, adding a mechanical peripheral thrombectomy platform to extend into adjacent vascular intervention indications.
The company's underlying technology relies on proprietary stent graft architectures, Nitinol-based delivery and sealing mechanisms, and a clinical evidence base of 16 trials and 2,000+ patients including two randomized controlled trials (LEOPARD and JAGUAR). Manufacturing is conducted in Irvine and Santa Rosa, California, with planned closure of a Milpitas facility in 2026 as part of post-bankruptcy restructuring. Endologix operates through subsidiaries in the Netherlands, Italy, and Poland, with sales coverage also in Germany, the UK, and Belgium.
Endologix generates revenue primarily through direct enterprise field sales of medical devices to hospitals and healthcare facilities, supported by in-procedure clinical support, Centers of Excellence training, and a reimbursement support center. Products are reimbursed under existing hospital and CMS payment frameworks (including a 2023 Transitional Pass-Through Payment for DETOUR). Customer segments include vascular surgeons, interventional cardiologists, and interventional radiologists performing EVAR, PTAB, and peripheral thrombectomy procedures, with targeted sub-segments in complex anatomies (short necks, small access vessels) and female EVAR patients historically underserved by conventional devices.
Endologix firmographics
Firmographics- Name
- Endologix
- Legal name
- Endologix LLC
- Website
- https://endologix.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Endologix is a US-headquartered, Deerfield-owned medical device company developing minimally invasive endovascular stent grafts and percutaneous bypass systems for abdominal aortic aneurysm repair and peripheral arterial disease, sold directly to hospitals and vascular specialists.
- Ownership category
- akta.pro rank
Endologix industry classification
Industry- Product category
- Vascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Endologix is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
Endologix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales: Endologix generates revenue through the sale of medical devices to hospitals and healthcare facilities. Commercial products include AFX2 Endovascular AAA System, ALTO Abdominal Stent Graft System, DETOUR System, and Pounce Thrombectomy System. Devices are sold directly to healthcare providers who perform procedures on patients.
- Professional Education Services: Endologix provides professional education and training programs for physicians including webinars, Centers of Excellence training, and VR procedural training sessions. These programs support adoption of company products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical devices for vascular procedures |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Endologix product offering
Product offeringCore offering
Endologix develops and manufactures minimally invasive medical devices for treating vascular disorders, including endovascular aneurysm repair (EVAR) systems for abdominal aortic aneurysms (AAA) and the DETOUR System for peripheral arterial disease (PAD). The company sells its products directly to hospitals and healthcare facilities, complemented by professional education, VR procedural training, and reimbursement support services.
Product overview
Endologix is a medical device company offering a portfolio of vascular intervention products. The portfolio centers on three commercial platforms: the DETOUR System (percutaneous transmural arterial bypass for long-segment PAD), the ALTO Abdominal Stent Graft System (EVAR with Adaptive Sealing Technology), and the AFX2 Endovascular AAA System (bifurcated unibody design EVAR). The company recently expanded its portfolio through the acquisition of the Pounce Thrombectomy System (FDA-cleared mechanical thrombectomy). Endologix also provides professional education services including VR procedural training and health economics/reimbursement support. The company operates under ownership of Deerfield Management with offices and manufacturing in California.
Differentiator
Problem solved
Functional benefit
Brands
- DETOUR: Percutaneous transmural arterial bypass (PTAB) system for treatment of long femoropopliteal lesions
- ALTO
- AFX2
- Pounce
Products and services
- DETOUR System First fully percutaneous transmural arterial bypass (PTAB) therapy for treating long-segment femoropopliteal lesions in PAD patients. Creates a femoropopliteal bypass routed through the femoral vein under fluoroscopic guidance. For vascular surgeons and interventionalists treating PAD patients who are suboptimal candidates for surgical bypass.
- ALTO Abdominal Stent Graft System EVAR device featuring exclusive Adaptive Sealing Technology that molds in-situ to the patient's specific aortic neck anatomy. Features the lowest profile device (13F inner diameter delivery system) and shortest neck length indication (7mm) for treating infrarenal abdominal aortic aneurysms with specialized anatomies. For vascular surgeons performing EVAR on AAA patients with challenging anatomy.
- AFX2 Endovascular AAA System Endovascular aneurysm repair (EVAR) device featuring a bifurcated unibody design that preserves native bifurcation and separates graft fixation from sealing zone. Utilizes ActiveSeal technology that conforms to the aortic wall. For vascular surgeons performing EVAR on AAA patients.
- Pounce Thrombectomy System FDA-cleared fully mechanical thrombectomy system for non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary dual-basket technology and a nitinol collection funnel, the system supports procedural simplicity without reliance on capital equipment, thrombolytics, or aspiration. Includes Pounce LP, Pounce, and Pounce XL configurations for various peripheral arterial vessel sizes. For interventionalists performing peripheral thrombectomy.
- VR Procedural Training Immersive virtual reality training programs for physicians to practice procedural steps safely. Supports the full Endologix portfolio including DETOUR System, ALTO Abdominal Stent Graft System, and AFX2 Endovascular AAA System procedures. Demonstrated 230% improvement compared to traditional training methods. For vascular surgeons and interventionalists learning Endologix procedures.
- DETOUR Health Economics and Reimbursement Support Comprehensive support including facility coding and reimbursement, physician coding and reimbursement, patient access, and claims review and assistance for the DETOUR System. For healthcare facilities and providers deploying the DETOUR System.
Quantifiable outcome
- 97.2% Freedom from secondary intervention due to graft occlusion at 5 years (ALTO/ENCORE)
- +5 more outcomes
Companies that use Endologix
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
Endologix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Endologix partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Surmodics, Inc.coreEndologix acquired the Pounce Thrombectomy System from Surmodics, Inc. The FDA-cleared mechanical thrombectomy platform uses proprietary dual-basket technology and nitinol collection funnel for non-surgical removal of thrombi and emboli from peripheral arteries. Transaction closed May 18, 2026. A core group of Surmodics employees supporting Pounce transitioned to Endologix.
- Steve DeitschminorOver 25 years of healthcare and medtech experience. Currently CEO of Caristo Diagnostics. Previously CFO of OrganOx, which he led through its $1.5 billion sale to Terumo Corporation in 2025 - the largest spinout exit in University of Oxford's history.
- Scott HuennekensminorFormer CEO of Volcano Corp. joined Endologix Board of Directors. Awarded EY's Entrepreneur of the Year award in 2010 and recognized by Goldman Sachs as one of the 100 most intriguing entrepreneurs.
- PQ Bypass, Inc.coreEndologix acquired PQ Bypass, Inc., adding the DETOUR System and TORUS Stent Graft to the company's product pipeline. The DETOUR System is a first-ever fully percutaneous transmural arterial bypass therapy for PAD.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Endologix competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Global medtech leader with the Endurant abdominal stent graft system and a broad peripheral vascular portfolio including IN.PACT drug-coated balloons and HawkOne atherectomy. Directly competes with Endologix in EVAR and is the entrenched market leader across vascular surgery.
- Terumo Aortic: Through Vascutek and Bolton, Terumo offers the Relay thoracic and abdominal stent graft systems that compete directly with Endologix's ALTO and AFX2, particularly in complex anatomies and international markets.
- Abbott Vascular: Major vascular device manufacturer offering XIENCE, Supera, and other peripheral products that overlap with Endologix's PAD and AAA portfolios, particularly through hospital purchasing agreements and integrated sales coverage.
Direct peers
- Cook Medical: Manufacturer of the Zenith abdominal and thoracic aortic stent graft systems, directly competing with Endologix in EVAR for AAA. Long-established player with deep vascular surgeon relationships globally.
- Penumbra: Developer of the Indigo mechanical thrombectomy system for peripheral and neurovascular indications, directly competing with the newly acquired Pounce Thrombectomy System in peripheral arterial thrombus removal.
- W. L. Gore & Associates: Manufacturer of the Gore Excluder AAA Endoprosthesis and Gore Viabahn endoprosthesis, one of the closest direct competitors to Endologix's AFX2 and ALTO in EVAR and a longstanding leader in stent graft technology for aortic disease.
Emerging players
- AngioDynamics: Developer of the Auryon atherectomy system and AlphaVac mechanical thrombectomy system, directly competing with Endologix's Pounce platform and PAD portfolio in peripheral vascular intervention.
- Artivion: Specialty cardiovascular and vascular surgery company offering aortic stent grafts (formerly CryoLife) that directly compete with Endologix in complex AAA and thoracic aortic disease, particularly for hostile anatomies.
- Surmodics: Former owner of the Pounce Thrombectomy System now acquired by Endologix. Surmodics continues to develop drug-coated balloon and surface-coating technologies relevant to vascular intervention and overlaps with Endologix in the broader peripheral space.
- Jandel Laboratories / Inari Medical: Acquired by Stryker in 2025, Inari Medical developed the FlowTriever system for venous thromboembolism and ClotTriever for thrombectomy, representing an adjacent emerging player in the mechanical thrombectomy category where Endologix's Pounce now competes.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Endologix social profiles
Digital presenceEndologix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endologix leadership team
Management profileNumber of profiles
Profiles12 records
Endologix subsidiaries and ownership
Company hierarchySubsidiaries4 records
Endologix funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endologix M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endologix
What does Endologix do?
Endologix develops and manufactures minimally invasive medical devices for treating vascular disorders, including endovascular aneurysm repair (EVAR) systems for abdominal aortic aneurysms (AAA) and the DETOUR System for peripheral arterial disease (PAD). The company sells its products directly to hospitals and healthcare facilities, complemented by professional education, VR procedural training, and reimbursement support services.
Is Endologix a public or private company?
Endologix is a private company. It is classified as private equity controlled and is currently operating.
When was Endologix founded?
Endologix was founded in 1992. It employs 501 to 1,000 people.
Where is Endologix based?
Endologix is headquartered in Irvine, United States, in the North America region.
How does Endologix make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are professional Education Services.
Who are Endologix's main competitors?
Broad incumbents on record are Medtronic, Terumo Aortic and Abbott Vascular. Direct peers are Cook Medical, Penumbra and W. L. Gore & Associates. Emerging players are AngioDynamics, Artivion, Surmodics and Jandel Laboratories / Inari Medical.
Does Endologix have an API?
No public API is recorded for Endologix.
What industry is Endologix in?
Endologix's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.